NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Elenco Azioni・Roche Holding AG

Roche Holding AG

Chiusa

SettoreSettore sanitario

325.6 0.74

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

325.4

Massimo

326.6

Metriche Chiave
By Trading Economics
Entrata	1.8B 5.5B
Vendite	15B 31B
P/E Media del settore	20.461 67.147
Rendimento da dividendi	2.97
Margine di Profitto	17.892
Dipendenti	103,249
EBITDA	5.1B 12B

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	2.97% 2.36%

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-28B 261B
Apertura precedente	324.86
Chiusura precedente	325.6

Notizie sul Sentiment di mercato

By Acuity

14%

86%

24 / 347 Classifica in Healthcare

Roche Holding AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 apr 2026, 07:46 UTC

Utili

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

23 apr 2026, 05:40 UTC

Utili

Roche Backs Full-Year View as Quarterly Sales Rise

9 mar 2026, 16:43 UTC

I principali Market Mover

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

9 mar 2026, 15:44 UTC

I principali Market Mover

Correction to Roche Shares Article

9 mar 2026, 09:51 UTC

I principali Market Mover

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

6 mar 2026, 09:24 UTC

I principali Market Mover

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

29 gen 2026, 10:07 UTC

Utili

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 gen 2026, 07:07 UTC

Utili

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

27 apr 2026, 09:54 UTC

Discorsi di Mercato

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

23 apr 2026, 08:10 UTC

Discorsi di Mercato

Utili

Roche Reports In Line Sales Figures -- Market Talk

23 apr 2026, 05:04 UTC

Utili

Roche Backs 2026 View

23 apr 2026, 05:04 UTC

Utili

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

23 apr 2026, 05:03 UTC

Utili

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

23 apr 2026, 05:02 UTC

Utili

Roche 1Q Group Sales Up 6% at Constant Currency

23 apr 2026, 05:02 UTC

Utili

Analysts Saw Roche 1Q Sales at CHF14.73B

23 apr 2026, 05:01 UTC

Utili

Roche 1Q Sales CHF14.72B

10 apr 2026, 11:28 UTC

Discorsi di Mercato

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

10 apr 2026, 11:17 UTC

Discorsi di Mercato

Roche to Face Significant Currency Headwinds -- Market Talk

11 mar 2026, 10:57 UTC

Discorsi di Mercato

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

9 mar 2026, 09:43 UTC

Azioni calde

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

6 mar 2026, 07:22 UTC

Discorsi di Mercato

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

3 mar 2026, 07:22 UTC

Discorsi di Mercato

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 mar 2026, 14:21 UTC

Discorsi di Mercato

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29 gen 2026, 11:40 UTC

Discorsi di Mercato

Utili

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 gen 2026, 06:05 UTC

Utili

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 gen 2026, 06:04 UTC

Utili

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 gen 2026, 06:03 UTC

Utili

Roche Issues 2026 View

29 gen 2026, 06:02 UTC

Utili

Analysts Saw 2025 Core EPS at CHF19.70

29 gen 2026, 06:02 UTC

Utili

Roche: 2025 Core EPS CHF19.46

29 gen 2026, 06:01 UTC

Utili

Analysts Had Seen 2025 Sales At CHF61.47B

Confronto tra pari

Modifica del prezzo

Roche Holding AG Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 0 che hanno fornito valutazioni azionarie a Roche Holding AG - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

24 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.